INSM Share Price

Open 15.30 Change Price %
High 15.68 1 Day 0.07 0.46
Low 15.00 1 Week 0.67 4.54
Close 15.42 1 Month 1.50 10.78
Volume 314665 1 Year 2.15 16.20
52 Week High 15.68
52 Week Low 9.02
INSM Important Levels
Resistance 2 16.05
Resistance 1 15.79
Pivot 15.37
Support 1 15.05
Support 2 14.79
NASDAQ USA Most Active Stocks
ASTI 0.01 0.00%
QCOM 54.88 -12.72%
QCOM 54.88 -12.72%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
EDMC 0.02 100.00%
CPSL 0.10 66.67%
LOCM 0.09 50.00%
ACFN 0.30 30.43%
LTRE 2.85 29.55%
WRES 0.09 28.57%
QKLS 0.14 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Insmed, Inc. (NASDAQ: INSM)

INSM Technical Analysis 5
As on 23rd Jan 2017 INSM Share Price closed @ 15.42 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 12.68 & Strong Buy for SHORT-TERM with Stoploss of 13.70 we also expect STOCK to react on Following IMPORTANT LEVELS.
INSM Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
INSM Other Details
Segment EQ
Market Capital 202974992.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.insmed.com
INSM Address
INSM
9 Deer Park Drive
Suite C
Monmouth Junction, NJ 08852
United States
Phone: 732-997-4600
INSM Latest News
Interactive Technical Analysis Chart Insmed, Inc. ( INSM NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Insmed, Inc.
INSM Business Profile
Insmed Incorporated is a biopharmaceutical company focused on patients suffering with lung diseases through the development and commercialization of targeted inhalation therapies. The Company�s lead candidate ARIKACE, is engineered to deliver anti-infective directly to the site of lung infections for at least two identified patient populations: cystic fibrosis (CF) patients with Pseudomonas aeuruginosa lung infections and patients with nontuberculous mycobacteria lung infections (NTM). During the year ended December 31, 2011, the Company was focused on its ARIKACE clinical development program, which includes a phase II clinical study of ARIKACE in patients with NTM lung disease (TARGET-NTM), as well as a European and Canadian registration phase III clinical study of ARIKACE in CF patients with Pseudomonas lung infections (CLEAR-108). ARIKACE is considered a New Chemical Entity by the United States Food and Drug Administration (FDA), primarily due to its liposomal technology.